The DOI matches its Crossref record; 140 of the 140 references it cites were found in a registry or an index.
The PI3K-Akt-mTOR Signaling Pathway in Human Acute Myeloid Leukemia (AML) Cells
Open accessAbstract
Acute myeloid leukemia (AML) is a heterogeneous group of diseases characterized by uncontrolled proliferation of hematopoietic stem cells in the bone marrow. Malignant cell growth is characterized by disruption of normal intracellular signaling, caused by mutations or aberrant external signaling. The phosphoinositide 3-kinase (PI3K)-Akt-mammalian target of rapamycin (mTOR) pathway (PI3K-Akt-mTOR pathway) is among one of the intracellular pathways aberrantly upregulated in cancers including AML. Activation of this pathway seems important in leukemogenesis, and given the central role of this pathway in metabolism, the bioenergetics of AML cells may depend on downstream signaling within this pathway. Furthermore, observations suggest that constitutive activation of the PI3K-Akt-mTOR pathway differs between patients, and that increased activity within this pathway is an adverse prognostic parameter in AML. Pharmacological targeting of the PI3K-Akt-mTOR pathway with specific inhibitors results in suppression of leukemic cell growth. However, AML patients seem to differ regarding their susceptibility to various small-molecule inhibitors, reflecting biological heterogeneity in the intracellular signaling status. These findings should be further investigated in both preclinical and clinical settings, along with the potential use of this pathway as a prognostic biomarker, both in patients receiving intensive curative AML treatment and in elderly/unfit receiving AML-stabilizing treatment.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hallmarks of Cancer: The Next Generation
Hanahan, D., & Weinberg, R. A. (2011) · Cell · doi:10.1016/j.cell.2011.02.013 · Cited by 66,590
Hanahan, D., & Weinberg, R. A. (2000) · Cell · doi:10.1016/s0092-8674(00)81683-9 · Cited by 29,219
Understanding the Warburg Effect: The Metabolic Requirements of Cell Proliferation
Vander Heiden, M. G., Cantley, L. C., & Thompson, C. B. (2009) · Science · doi:10.1126/science.1160809 · Cited by 16,197
Arber, D. A., Orazi, A., Hasserjian, R., Thiele, J., Borowitz, M. J., Le Beau, M. M., Bloomfield, C. D., Cazzola, M., & Vardiman, J. W. (2016) · Blood · doi:10.1182/blood-2016-03-643544 · Cited by 10,119
mTOR Signaling in Growth, Metabolism, and Disease
Saxton, R. A., & Sabatini, D. M. (2017) · Cell · doi:10.1016/j.cell.2017.02.004 · Cited by 7,555
AKT/PKB signaling: navigating downstream
Manning, B. D., & Cantley, L. C. (2007) · Cell · doi:10.1016/j.cell.2007.06.009 · Cited by 6,115
Bonnet, D., & Dick, J. E. (1997) · Nature Medicine · doi:10.1038/nm0797-730 · Cited by 5,864
Döhner, H., Estey, E., Grimwade, D., Amadori, S., Appelbaum, F. R., Büchner, T., Dombret, H., Ebert, B. L., Fenaux, P., Larson, R. A., et al. (2017) · Blood · doi:10.1182/blood-2016-08-733196 · Cited by 5,775
Genomic and Epigenomic Landscapes of Adult De Novo Acute Myeloid Leukemia
The Cancer Genome Atlas Research Network (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1301689 · Cited by 5,078
Mutational landscape and significance across 12 major cancer types
Kandoth, C., McLellan, M. D., Vandin, F., Ye, K., Niu, B., Lu, C., Xie, M., Zhang, Q., McMichael, J. F., Wyczalkowski, M. A., et al. (2013) · Nature · doi:10.1038/nature12634 · Cited by 4,419
Genomic classification and prognosis in acute myeloid leukemia
Papaemmanuil, E., Gerstung, M., Bullinger, L., Gaidzik, V. I., Paschka, P., Roberts, N. D., Potter, N. E., Heuser, M., Thol, F., Bolli, N., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1516192 · Cited by 4,350 · cited 2×
“The numbers of mutant signaling proteins identified in AML are high [9], although are more likely to reflect activation of a limited number of downstream effector pathways [115].”
BackgroundKim, J.-W., Tchernyshyov, I., Semenza, G. L., & Dang, C. V. (2006) · Cell Metabolism · doi:10.1016/j.cmet.2006.02.002 · Cited by 3,905
Döhner, H., Weisdorf, D. J., & Bloomfield, C. D. (2015) · New England Journal of Medicine · doi:10.1056/nejmra1406184 · Cited by 3,306
Pan-cancer analysis of whole genomes
The ICGC/TCGA Pan-Cancer Analysis of Whole Genomes Consortium, Aaltonen, L. A., Abascal, F., Abeshouse, A., Aburatani, H., Adams, D. J., Agrawal, N., Ahn, K. S., Ahn, S.-M., Aikata, H., et al. (2020) · Nature · doi:10.1038/s41586-020-1969-6 · Cited by 3,064
mTOR Inhibition Induces Upstream Receptor Tyrosine Kinase Signaling and Activates Akt
O'Reilly, K. E., Rojo, F., She, Q.-B., Solit, D., Mills, G. B., Smith, D., Lane, H., Hofmann, F., Hicklin, D. J., Ludwig, D. L., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-2925 · Cited by 2,561
Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a FLT3 Mutation
Stone, R. M., Mandrekar, S. J., Sanford, B. L., Laumann, K., Geyer, S., Bloomfield, C. D., Thiede, C., Prior, T. W., Döhner, K., Marcucci, G., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1614359 · Cited by 2,250
Exploiting the PI3K/AKT Pathway for Cancer Drug Discovery
Hennessy, B. T., Smith, D. L., Ram, P. T., Lu, Y., & Mills, G. B. (2005) · Nature Reviews Drug Discovery · doi:10.1038/nrd1902 · Cited by 2,185
Protein kinase B (c-Akt) in phosphatidylinositol-3-OH kinase signal transduction
Burgering, B. M. T., & Coffer, P. J. (1995) · Nature · doi:10.1038/376599a0 · Cited by 2,089
mTOR Signaling in Growth, Metabolism, and Disease
Saxton, R. A., & Sabatini, D. M. (2017) · Cell · doi:10.1016/j.cell.2017.03.035 · Cited by 2,070
Activation of a metabolic gene regulatory network downstream of mTOR complex 1
Düvel, K., Yecies, J. L., Menon, S., Raman, P., Lipovsky, A. I., Souza, A. L., Triantafellow, E., Ma, Q., Gorski, R., Cleaver, S., et al. (2010) · Molecular Cell · doi:10.1016/j.molcel.2010.06.022 · Cited by 2,020
Phosphatidylinositol-3-OH kinase direct target of Ras
Rodriguez-Viciana, P., Warne, P. H., Dhand, R., Vanhaesebroeck, B., Gout, I., Fry, M. J., Waterfield, M. D., & Downward, J. (1994) · Nature · doi:10.1038/370527a0 · Cited by 1,954
DiNardo, C. D., Pratz, K., Pullarkat, V., Jonas, B. A., Arellano, M., Becker, P. S., Frankfurt, O., Konopleva, M., Wei, A. H., Kantarjian, H. M., et al. (2019) · Blood · doi:10.1182/blood-2018-08-868752 · Cited by 1,825
The Ras-ERK and PI3K-mTOR pathways: cross-talk and compensation
Mendoza, M. C., Er, E. E., & Blenis, J. (2011) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2011.03.006 · Cited by 1,817
PI3K and cancer: lessons, challenges and opportunities
Fruman, D. A., & Rommel, C. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4204 · Cited by 1,709
Primary Bioassay of Human Tumor Stem Cells
Hamburger, A. W., & Salmon, S. E. (1977) · Science · doi:10.1126/science.560061 · Cited by 1,643
Retinoic Acid and Arsenic Trioxide for Acute Promyelocytic Leukemia
Lo-Coco, F., Avvisati, G., Vignetti, M., Thiede, C., Orlando, S. M., Iacobelli, S., Ferrara, F., Fazi, P., Cicconi, L., Di Bona, E., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1300874 · Cited by 1,611
Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia
Stein, E. M., DiNardo, C. D., Pollyea, D. A., Fathi, A. T., Roboz, G. J., Altman, J. K., Stone, R. M., DeAngelo, D. J., Levine, R. L., Flinn, I. W., et al. (2017) · Blood · doi:10.1182/blood-2017-04-779405 · Cited by 1,516
Akt Stimulates Aerobic Glycolysis in Cancer Cells
Elstrom, R. L., Bauer, D. E., Buzzai, M., Karnauskas, R., Harris, M. H., Plas, D. R., Zhuang, H., Cinalli, R. M., Alavi, A., Rudin, C. M., et al. (2004) · Cancer Research · doi:10.1158/0008-5472.can-03-2904 · Cited by 1,454
Durable Remissions with Ivosidenib in IDH1 -Mutated Relapsed or Refractory AML
DiNardo, C. D., Stein, E. M., de Botton, S., Roboz, G. J., Altman, J. K., Mims, A. S., Swords, R., Collins, R. H., Mannis, G. N., Pollyea, D. A., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1716984 · Cited by 1,454
Jacinto, E., Facchinetti, V., Liu, D., Soto, N., Wei, S., Jung, S. Y., Huang, Q., Qin, J., & Su, B. (2006) · Cell · doi:10.1016/j.cell.2006.08.033 · Cited by 1,410
‘Acute myeloid leukemia: a comprehensive review and 2016 update’
De Kouchkovsky, I., & Abdul-Hay, M. (2016) · Blood Cancer Journal · doi:10.1038/bcj.2016.50 · Cited by 1,317
The nuts and bolts of AGC protein kinases
Pearce, L. R., Komander, D., & Alessi, D. R. (2010) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2822 · Cited by 1,294
Gilteritinib or Chemotherapy for Relapsed or Refractory FLT3 -Mutated AML
Perl, A. E., Martinelli, G., Cortes, J. E., Neubauer, A., Berman, E., Paolini, S., Montesinos, P., Baer, M. R., Larson, R. A., Ustun, C., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1902688 · Cited by 1,287
Peterson, T. R., Laplante, M., Thoreen, C. C., Sancak, Y., Kang, S. A., Kuehl, W. M., Gray, N. S., & Sabatini, D. M. (2009) · Cell · doi:10.1016/j.cell.2009.03.046 · Cited by 1,202
Dombret, H., Seymour, J. F., Butrym, A., Wierzbowska, A., Selleslag, D., Jang, J. H., Kumar, R., Cavenagh, J., Schuh, A. C., Candoni, A., et al. (2015) · Blood · doi:10.1182/blood-2015-01-621664 · Cited by 1,165
Targeting FLT3 mutations in AML: review of current knowledge and evidence
Daver, N., Schlenk, R. F., Russell, N. H., & Levis, M. J. (2019) · Leukemia · doi:10.1038/s41375-018-0357-9 · Cited by 1,075
Stem cell gene expression programs influence clinical outcome in human leukemia
Eppert, K., Takenaka, K., Lechman, E. R., Waldron, L., Nilsson, B., van Galen, P., Metzeler, K. H., Poeppl, A., Ling, V., Beyene, J., et al. (2011) · Nature Medicine · doi:10.1038/nm.2415 · Cited by 1,041
Rheb Binds and Regulates the mTOR Kinase
Long, X., Lin, Y., Ortiz-Vega, S., Yonezawa, K., & Avruch, J. (2005) · Current Biology · doi:10.1016/j.cub.2005.02.053 · Cited by 1,005
Regulation of cap-dependent translation by eIF4E inhibitory proteins
Richter, J. D., & Sonenberg, N. (2005) · Nature · doi:10.1038/nature03205 · Cited by 970
Hope, K. J., Jin, L., & Dick, J. E. (2004) · Nature Immunology · doi:10.1038/ni1080 · Cited by 968
Farge, T., Saland, E., de Toni, F., Aroua, N., Hosseini, M., Perry, R., Bosc, C., Sugita, M., Stuani, L., Fraisse, M., et al. (2017) · Cancer Discovery · doi:10.1158/2159-8290.cd-16-0441 · Cited by 912
Signaling by Distinct Classes of Phosphoinositide 3-Kinases
Vanhaesebroeck, B., & Waterfield, M. D. (1999) · Experimental Cell Research · doi:10.1006/excr.1999.4701 · Cited by 853
Kunz, J., Henriquez, R., Schneider, U., Deuter-Reinhard, M., Movva, N. R., & Hall, M. N. (1993) · Cell · doi:10.1016/0092-8674(93)90144-f · Cited by 834
Serra, V., Markman, B., Scaltriti, M., Eichhorn, P. J. A., Valero, V., Guzman, M., Botero, M. L., Llonch, E., Atzori, F., Di Cosimo, S., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-1385 · Cited by 787
ERK implication in cell cycle regulation
Chambard, J.-C., Lefloch, R., Pouysségur, J., & Lenormand, P. (2007) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2006.11.010 · Cited by 750
Roux, P. P., Ballif, B. A., Anjum, R., Gygi, S. P., & Blenis, J. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0405659101 · Cited by 750
Hills, R. K., Castaigne, S., Appelbaum, F. R., Delaunay, J., Petersdorf, S., Othus, M., Estey, E. H., Dombret, H., Chevret, S., Ifrah, N., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70281-5 · Cited by 721
mSin1 Is Necessary for Akt/PKB Phosphorylation, and Its Isoforms Define Three Distinct mTORC2s
Frias, M. A., Thoreen, C. C., Jaffe, J. D., Schroder, W., Sculley, T., Carr, S. A., & Sabatini, D. M. (2006) · Current Biology · doi:10.1016/j.cub.2006.08.001 · Cited by 695
Sanz, M. A., Fenaux, P., Tallman, M. S., Estey, E. H., Löwenberg, B., Naoe, T., Lengfelder, E., Döhner, H., Burnett, A. K., Chen, S.-J., et al. (2019) · Blood · doi:10.1182/blood-2019-01-894980 · Cited by 664
Coexistence of LMPP-like and GMP-like Leukemia Stem Cells in Acute Myeloid Leukemia
Goardon, N., Marchi, E., Atzberger, A., Quek, L., Schuh, A., Soneji, S., Woll, P., Mead, A., Alford, K. A., Rout, R., et al. (2011) · Cancer Cell · doi:10.1016/j.ccr.2010.12.012 · Cited by 653
Burnett, A. K., Milligan, D., Prentice, A. G., Goldstone, A. H., McMullin, M. F., Hills, R. K., & Wheatley, K. (2007) · Cancer · doi:10.1002/cncr.22496 · Cited by 619
Cancer stem cells: lessons from leukemia
Wang, J. C. Y., & Dick, J. E. (2005) · Trends in Cell Biology · doi:10.1016/j.tcb.2005.07.004 · Cited by 615
Alessi, D. R., Kozlowski, M. T., Weng, Q.-P., Morrice, N., & Avruch, J. (1998) · Current Biology · doi:10.1016/s0960-9822(98)70037-5 · Cited by 574
Targeting Aberrant RAS/RAF/MEK/ERK Signaling for Cancer Therapy
Degirmenci, U., Wang, M., & Hu, J. (2020) · Cells · doi:10.3390/cells9010198 · Cited by 534
Miyamoto, T., Weissman, I. L., & Akashi, K. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.97.13.7521 · Cited by 465
Dissecting the role of mTOR: Lessons from mTOR inhibitors
Dowling, R. J. O., Topisirovic, I., Fonseca, B. D., & Sonenberg, N. (2010) · Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics · doi:10.1016/j.bbapap.2009.12.001 · Cited by 454
Kim, J. E., & Chen, J. (2004) · Diabetes · doi:10.2337/diabetes.53.11.2748 · Cited by 454
Targeting ERK, an Achilles' Heel of the MAPK pathway, in cancer therapy
Liu, F., Yang, X., Geng, M., & Huang, M. (2018) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2018.01.008 · Cited by 432
Cancer cell metabolism: implications for therapeutic targets
Jang, M., Kim, S. S., & Lee, J. (2013) · Experimental & Molecular Medicine · doi:10.1038/emm.2013.85 · Cited by 397
Survival of acute myeloid leukemia cells requires PI3 kinase activation
Xu, Q., Simpson, S.-E., Scialla, T. J., Bagg, A., & Carroll, M. (2003) · Blood · doi:10.1182/blood-2002-11-3429 · Cited by 394
Rheb Activates mTOR by Antagonizing Its Endogenous Inhibitor, FKBP38
Bai, X., Ma, D., Liu, A., Shen, X., Wang, Q. J., Liu, Y., & Jiang, Y. (2007) · Science · doi:10.1126/science.1147379 · Cited by 382
Taussig, D. C., Vargaftig, J., Miraki-Moud, F., Griessinger, E., Sharrock, K., Luke, T., Lillington, D., Oakervee, H., Cavenagh, J., Agrawal, S. G., et al. (2010) · Blood · doi:10.1182/blood-2009-02-206565 · Cited by 366
Pharmacologic Characterization of a Potent Inhibitor of Class I Phosphatidylinositide 3-Kinases
Raynaud, F. I., Eccles, S., Clarke, P. A., Hayes, A., Nutley, B., Alix, S., Henley, A., Di-Stefano, F., Ahmad, Z., Guillard, S., et al. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-4615 · Cited by 352
Isocitrate dehydrogenase mutations in myeloid malignancies
Medeiros, B. C., Fathi, A. T., DiNardo, C. D., Pollyea, D. A., Chan, S. M., & Swords, R. (2017) · Leukemia · doi:10.1038/leu.2016.275 · Cited by 350
The activation of phosphatidylinositol 3-kinase by Ras
Kodaki, T., Woscholski, R., Hallberg, B., Rodriguez-Viciana Julian Downward, P., & Parker, P. J. (1994) · Current Biology · doi:10.1016/s0960-9822(00)00177-9 · Cited by 329
Role of the PI3K/AKT and mTOR signaling pathways in acute myeloid leukemia
Park, S., Chapuis, N., Tamburini, J., Bardet, V., Cornillet-Lefebvre, P., Willems, L., Green, A., Mayeux, P., Lacombe, C., & Bouscary, D. (2010) · Haematologica · doi:10.3324/haematol.2009.013797 · Cited by 306
A distinct glucose metabolism signature of acute myeloid leukemia with prognostic value
Chen, W.-L., Wang, J.-H., Zhao, A.-H., Xu, X., Wang, Y.-H., Chen, T.-L., Li, J.-M., Mi, J.-Q., Zhu, Y.-M., Liu, Y.-F., et al. (2014) · Blood · doi:10.1182/blood-2014-02-554204 · Cited by 302
Zhang, J., Gao, Z., Yin, J., Quon, M. J., & Ye, J. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m806480200 · Cited by 297
How I treat acute myeloid leukemia in the era of new drugs
DiNardo, C. D., & Wei, A. H. (2020) · Blood · doi:10.1182/blood.2019001239 · Cited by 290
Yee, K. W. L., Zeng, Z., Konopleva, M., Verstovsek, S., Ravandi, F., Ferrajoli, A., Thomas, D., Wierda, W., Apostolidou, E., Albitar, M., et al. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-0764 · Cited by 285
Signaling in Control of Cell Growth and Metabolism
Ward, P. S., & Thompson, C. B. (2012) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a006783 · Cited by 270
ERK1/2 Phosphorylate Raptor to Promote Ras-dependent Activation of mTOR Complex 1 (mTORC1)
Carriere, A., Romeo, Y., Acosta-Jaquez, H. A., Moreau, J., Bonneil, E., Thibault, P., Fingar, D. C., & Roux, P. P. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.159046 · Cited by 268
Myeloid Sarcoma: Presentation, Diagnosis, and Treatment
Almond, L. M., Charalampakis, M., Ford, S. J., Gourevitch, D., & Desai, A. (2017) · Clinical Lymphoma Myeloma and Leukemia · doi:10.1016/j.clml.2017.02.027 · Cited by 266
Kornblau, S. M., Womble, M., Qiu, Y. H., Jackson, C. E., Chen, W., Konopleva, M., Estey, E. H., & Andreeff, M. (2006) · Blood · doi:10.1182/blood-2006-02-003475 · Cited by 265
Functional proteomic profiling of AML predicts response and survival
Kornblau, S. M., Tibes, R., Qiu, Y. H., Chen, W., Kantarjian, H. M., Andreeff, M., Coombes, K. R., & Mills, G. B. (2009) · Blood · doi:10.1182/blood-2007-10-119438 · Cited by 263
Sujobert, P. (2005) · Blood · doi:10.1182/blood-2004-08-3225 · Cited by 245
FLT3 mutations in acute myeloid leukemia: what is the best approach in 2013?
Levis, M. (2013) · Hematology · doi:10.1182/asheducation-2013.1.220 · Cited by 243
Rizzieri, D. A., Feldman, E., DiPersio, J. F., Gabrail, N., Stock, W., Strair, R., Rivera, V. M., Albitar, M., Bedrosian, C. L., & Giles, F. J. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-1372 · Cited by 222
Tamburini, J., Chapuis, N., Bardet, V., Park, S., Sujobert, P., Willems, L., Ifrah, N., Dreyfus, F., Mayeux, P., Lacombe, C., et al. (2008) · Blood · doi:10.1182/blood-2007-03-080796 · Cited by 221
Brandts, C. H., Sargin, B., Rode, M., Biermann, C., Lindtner, B., Schwäble, J., Buerger, H., Müller-Tidow, C., Choudhary, C., McMahon, M., et al. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-0422 · Cited by 212
Kuo, T.-C., Tian, T.-F., & Tseng, Y. J. (2013) · BMC Systems Biology · doi:10.1186/1752-0509-7-64 · Cited by 196
Min, Y. H., Eom, J. I., Cheong, J. W., Maeng, H. O., Kim, J. Y., Jeung, H. K., Lee, S. T., Lee, M. H., Hahn, J. S., & Ko, Y. W. (2003) · Leukemia · doi:10.1038/sj.leu.2402874 · Cited by 192
Samudio, I., Fiegl, M., McQueen, T., Clise-Dwyer, K., & Andreeff, M. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-0555 · Cited by 168
Leukemia-associated antigens and their relevance to the immunotherapy of acute myeloid leukemia
Anguille, S., Van Tendeloo, V. F., & Berneman, Z. N. (2012) · Leukemia · doi:10.1038/leu.2012.145 · Cited by 168
mTOR regulates cell survival after etoposide treatment in primary AML cells
Xu, Q., Thompson, J. E., & Carroll, M. P. (2005) · Blood · doi:10.1182/blood-2004-11-4468 · Cited by 165
Syk inhibitors in clinical development for hematological malignancies
Liu, D., & Mamorska-Dyga, A. (2017) · Journal of Hematology & Oncology · doi:10.1186/s13045-017-0512-1 · Cited by 164
Bellacosa, A., Testa, J. R., moore, R., & Larue, L. (2004) · Cancer Biology & Therapy · doi:10.4161/cbt.3.3.703 · Cited by 162
SYK Is a Critical Regulator of FLT3 in Acute Myeloid Leukemia
Puissant, A., Fenouille, N., Alexe, G., Pikman, Y., Bassil, C. F., Mehta, S., Du, J., Kazi, J. U., Luciano, F., Rönnstrand, L., et al. (2014) · Cancer Cell · doi:10.1016/j.ccr.2014.01.022 · Cited by 162
Targeting the Bcl-2 Family in B Cell Lymphoma
Adams, C. M., Clark-Garvey, S., Porcu, P., & Eischen, C. M. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2018.00636 · Cited by 159
Calling in SYK: SYK's dual role as a tumor promoter and tumor suppressor in cancer
Krisenko, M. O., & Geahlen, R. L. (2014) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2014.10.022 · Cited by 157
Billottet, C., Grandage, V., Gale, R. E., Quattropani, A., Rommel, C., Vanhaesebroeck, B., & Khwaja, A. (2006) · Oncogene · doi:10.1038/sj.onc.1209670 · Cited by 155
Clinical development of demethylating agents in hematology
Navada, S. C., Lohmeyer, J. K., Lübbert, M., & Silverman, L. R. (2014) · Journal of Clinical Investigation · doi:10.1172/jci69739 · Cited by 150
Prognostic significance of 2-hydroxyglutarate levels in acute myeloid leukemia in China
Wang, J.-H., Chen, W., Li, J., Wu, S., Chen, T., Zhu, Y., Zhang, W., Li, Y., Qiu, Y.-P., Zhao, A.-H., et al. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1315558110 · Cited by 148
Chapuis, N., Tamburini, J., Cornillet‐Lefèbvre, P., Gillot, L., Bardet, V., Willems, L., Park, S., Green, A. S., Ifrah, N., Dreyfus, F., et al. (2009) · Haematologica · doi:10.3324/haematol.2009.010785 · Cited by 147
Poulain, L., Sujobert, P., Zylbersztejn, F., Barreau, S., Stuani, L., Lambert, M., Palama, T. L., Chesnais, V, Birsen, R., Vergez, F., et al. (2017) · Leukemia · doi:10.1038/leu.2017.81 · Cited by 145
Activation of Phosphoinositide 3-Kinase γ by Ras
Suire, S., Hawkins, P. T., & Stephens, L. (2002) · Current Biology · doi:10.1016/s0960-9822(02)00933-8 · Cited by 143
Outlook on PI3K/AKT/mTOR inhibition in acute leukemia
Fransecky, L. R., Mochmann, L. H., & Baldus, C. D. (2015) · Molecular and Cellular Therapies · doi:10.1186/s40591-015-0040-8 · Cited by 135
Gallay, N., Santos, C. D., Cuzin, L., Bousquet, M., Gouy, V. S., Chaussade, C., Attal, M., Payrastre, B., Demur, C., & Récher, C. (2009) · Leukemia · doi:10.1038/leu.2008.395 · Cited by 130
Tamburini, J., Elie, C., Bardet, V., Chapuis, N., Park, S., Broët, P., Cornillet-Lefebvre, P., Lioure, B., Ugo, V., Blanchet, O., et al. (2007) · Blood · doi:10.1182/blood-2006-12-061283 · Cited by 120
Bruserud, Ø., Gjertsen, B. T., Foss, B., & Huang, T. (2001) · Stem Cells · doi:10.1634/stemcells.19-1-1 · Cited by 117
Herst, P. M., Howman, R., Neeson, P. J., Berridge, M. V., & Ritchie, D. S. (2010) · Journal of Leukocyte Biology · doi:10.1189/jlb.0710417 · Cited by 116
Chen, W., Drakos, E., Grammatikakis, I., Schlette, E. J., Jiang, L., Leventaki, V., Staikou-Drakopoulou, E., Patsouris, E., Panayiotidis, P. G., Medeiros, L. J., et al. (2010) · Molecular Cancer · doi:10.1186/1476-4598-9-292 · Cited by 110
Perl, A. E., Kasner, M. T., Tsai, D. E., Vogl, D. T., Loren, A. W., Schuster, S. J., Porter, D. L., Stadtmauer, E. A., Goldstein, S. C., Frey, N. V., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-0842 · Cited by 110
Human acute myeloid leukemia stem cells
Hope, K. J., Jin, L., & Dick, J. E. (2003) · Archives of Medical Research · doi:10.1016/j.arcmed.2003.08.007 · Cited by 103
AKT and ERK1/2 signaling in intrahepatic cholangiocarcinoma
Schmitz, K., Lang, H., Wohlschlaeger, J., Sotiropoulos, G. C., Reis, H., Schmid, K. W., & Baba, H. (2007) · World Journal of Gastroenterology · doi:10.3748/wjg.13.6470 · Cited by 90
mTOR, A New Therapeutic Target in Acute Myeloid Leukemia
Récher, C., Santos, C. D., Demur, C., & Payrastre, B. (2005) · Cell Cycle · doi:10.4161/cc.4.11.2159 · Cited by 89
Dueling for dual inhibition: Means to enhance effectiveness of PI3K/Akt/mTOR inhibitors in AML
Herschbein, L., & Liesveld, J. L. (2017) · Blood Reviews · doi:10.1016/j.blre.2017.11.006 · Cited by 86
Targeting PDK1 with dichloroacetophenone to inhibit acute myeloid leukemia (AML) cell growth
Qin, L., Tian, Y., Yu, Z., Shi, D., Wang, J., Zhang, C., Peng, R., Chen, X., Liu, C., Chen, Y., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.6366 · Cited by 82
Optimal targeting of the mTORC1 kinase in human cancer
Lane, H. A., & Breuleux, M. (2009) · Current Opinion in Cell Biology · doi:10.1016/j.ceb.2009.01.016 · Cited by 76
Biology and Clinical Relevance of Acute Myeloid Leukemia Stem Cells
Reinisch, A., Chan, S. M., Thomas, D., & Majeti, R. (2015) · Seminars in Hematology · doi:10.1053/j.seminhematol.2015.03.008 · Cited by 73
Amadori, S., Stasi, R., Martelli, A. M., Venditti, A., Meloni, G., Pane, F., Martinelli, G., Lunghi, M., Pagano, L., Cilloni, D., et al. (2011) · British Journal of Haematology · doi:10.1111/j.1365-2141.2011.08940.x · Cited by 72
Nepstad, I., Hatfield, K. J., Grønningsæter, I. S., Aasebø, E., Hernandez-Valladares, M., Hagen, K. M., Rye, K. P., Berven, F. S., Selheim, F., Reikvam, H., et al. (2019) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-019-0050-0 · Cited by 71
Self-citationRecent advances in the understanding and treatment of acute myeloid leukemia
Watts, J. M., & Nimer, S. D. (2018) · F1000Research · doi:10.12688/f1000research.14116.1 · Cited by 63
Kubota, Y., Ohnishi, H., Kitanaka, A., Ishida, T., & Tanaka, T. (2004) · Leukemia · doi:10.1038/sj.leu.2403402 · Cited by 60
SYK regulates mTOR signaling in AML
Carnevale, J. C., Ross, L., Puissant, A., Banerji, V., Stone, R. M., DeAngelo, D. J., Ross, K. N., & Stegmaier, K. (2013) · Leukemia · doi:10.1038/leu.2013.89 · Cited by 58
Phase II Trial of MEK Inhibitor Binimetinib (MEK162) in RAS-mutant Acute Myeloid Leukemia
Maiti, A., Naqvi, K., Kadia, T. M., Borthakur, G. M., Takahashi, K., Bose, P., Daver, N. G., Patel, A. P., Alvarado, Y., Ohanian, M. N., et al. (2018) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2018.12.009 · Cited by 57
PI3K keeps the balance between metabolism and cancer
Braccini, L., Ciraolo, E., Martini, M., Pirali, T., Germena, G., Rolfo, K., & Hirsch, E. (2012) · Advances in Biological Regulation · doi:10.1016/j.jbior.2012.04.002 · Cited by 55
Piddock, R. E., Bowles, K. M., & Rushworth, S. A. (2017) · Cancers · doi:10.3390/cancers9040029 · Cited by 55
Watanabe, D., Nogami, A., Okada, K., Akiyama, H., Umezawa, Y., & Miura, O. (2019) · Cancers · doi:10.3390/cancers11121827 · Cited by 50
Reikvam, H., Nepstad, I., Bruserud, Ø., & Hatfield, K. J. (2013) · Oncotarget · doi:10.18632/oncotarget.971 · Cited by 47
Self-citationProud, C. G. (2007) · Science · doi:10.1126/science.1150653 · Cited by 46
BEZ235: When Promising Science Meets Clinical Reality
Pongas, G., & Fojo, T. (2016) · The Oncologist · doi:10.1634/theoncologist.2016-0243 · Cited by 43
Nepstad, I., Hatfield, K. J., Tvedt, T. H. A., Reikvam, H., & Bruserud, Ø. (2018) · Cancers · doi:10.3390/cancers10090332 · Cited by 42
Self-citationRheb G-Proteins and the Activation of mTORC1
(2010) · The Enzymes · doi:10.1016/s1874-6047(10)27003-8 · Cited by 41
Splenic tyrosine kinase (SYK) inhibitors and their possible use in acute myeloid leukemia
Bartaula-Brevik, S., Brattås, M. K., Tvedt, T. H. A., Reikvam, H., & Bruserud, Ø. (2018) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2018.1459562 · Cited by 40
Self-citationReikvam, H., Tamburini, J., Skrede, S., Holdhus, R., Poulain, L., Ersvær, E., Hatfield, K. J., & Bruserud, Ø. (2013) · British Journal of Haematology · doi:10.1111/bjh.12611 · Cited by 36
Self-citationGrønningsæter, I. S., Fredly, H., Gjertsen, B. T., Hatfield, K. J., & Bruserud, Ø. (2019) · Cells · doi:10.3390/cells8101229 · Cited by 33
Self-citationRational Combinations of Targeted Agents in AML
Bose, P., & Grant, S. (2015) · Journal of Clinical Medicine · doi:10.3390/jcm4040634 · Cited by 32
Syk Regulates Multiple Signaling Pathways Leading to CX3CL1 Chemotaxis in Macrophages
Park, H., & Cox, D. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.185181 · Cited by 29
Nepstad, I., Reikvam, H., Brenner, A. K., Bruserud, Ø., & Hatfield, K. J. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19020382 · Cited by 27
Self-citationReikvam, H., Aasebø, E., Brenner, A. K., Bartaula-Brevik, S., Grønningsæter, I. S., Forthun, R. B., Hovland, R., & Bruserud, Ø. (2019) · Journal of Clinical Medicine · doi:10.3390/jcm8070970 · Cited by 26
Self-citationTsykunova, G., Reikvam, H., Hovland, R., & Bruserud, Ø. (2011) · Leukemia · doi:10.1038/leu.2011.243 · Cited by 21
Self-citationSignalling mechanisms that regulate metabolic profile and autophagy of acute myeloid leukaemia cells
Pereira, O., Teixeira, A., Sampaio‐Marques, B., Castro, I., Girão, H., & Ludovico, P. (2018) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.13737 · Cited by 20
Hypomethylating Agents in the Treatment of Myelodysplastic Syndromes and Myeloid Leukemia
Szmigielska‐Kapłon, A., & Robak, T. (2011) · Current Cancer Drug Targets · doi:10.2174/156800911796798940 · Cited by 19
Nepstad, I., Hatfield, K. J., Aasebø, E., Hernandez-Valladares, M., Brenner, A. K., Bartaula-Brevik, S., Berven, F. S., Selheim, F., Skavland, J., Gjertsen, B. T., et al. (2018) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2018.1487401 · Cited by 19
Self-citationBrandwein, J. M., Zhu, N. Y., Kumar, R., Leber, B. F., Sabloff, M., Sandhu, I., Kassis, J., Olney, H. J., Elemary, M., & Schuh, A. C. (2017) · Europe PMC (PubMed Central) · Cited by 18
Reikvam, H., Nepstad, I., & Tamburini, J. (2013) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2013.841137 · Cited by 10
Self-citationShivarov, V. S., Dolnik, A., Lang, K. M. H., Krönke, J., Kuchenbauer, F. C., Paschka, P., Gaidzik, V. I., Döhner, H., Schlenk, R. F., Döhner, K., et al. (2016) · Haematologica · doi:10.3324/haematol.2016.146555 · Cited by 10
Singh, R. (2016) · FEBS Open Bio · doi:10.1002/2211-5463.12149 · Cited by 9
Mass spectrometry in leukemia research and treatment
Roboz, J., & Roboz, G. J. (2015) · Expert Review of Hematology · doi:10.1586/17474086.2015.1018889 · Cited by 6
Cited by
Sanz, M. A., Fenaux, P., Tallman, M. S., Estey, E. H., Löwenberg, B., Naoe, T., Lengfelder, E., Döhner, H., Burnett, A. K., Chen, S.-J., et al. (2019) · Blood · doi:10.1182/blood-2019-01-894980 · Cited by 664
The role of PD-1/PD-L1 and application of immune-checkpoint inhibitors in human cancers
Tang, Q., Chen, Y., Li, X., Long, S., Shi, Y., Yu, Y., Wu, W., Han, L., & Wang, S. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.964442 · Cited by 561
Metadata
- Authors
- Nepstad, I., Hatfield, K. J., Grønningsæter, I. S., & Reikvam, H.
- Venue
- International Journal of Molecular Sciences
- Publisher
- MDPI AG
- Published
- 2020-04-21
- Volume
- 21
- Issue
- 8
- Pages
- 2907
- ISSN
- 1422-0067 (ISSN-L)
- OpenAlex
- W3020803734
- Cited by
- 348
- References
- 140
- FWCI
- 12.59
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.